Allos Pharma
Pharmaceuticals - , ,
Allos Pharma Employees
Allos Pharma Senior Management
Allos Pharma Details
We are a global team dedicated to improve the lives of patients with Fragile X Syndrome and Autism Spectrum Disorder. Our work spans three decades of research in neuroscience and intellectual disabilities. The "mGluR theory of fragile X" proposed by MIT Professor Mark Bear and collaborators in 2004 is widely considered to be a key conceptual breakthrough, and laid the foundation for development of disease-modifying therapies for treatment of Fragile X Syndrome and Autism Spectrum Disorder. Allos Pharma is committed to develop and market the first approved therapy in Fragile X Syndrome.The name Allos Pharma is derived fromallistic, meaning not autistic.
Allos Pharma Technologies
Load Balancers
Apache
CMS
WordPress.org
Fonts
Google Font API
Analytics and Tracking
Google Analytics
Other
Mobile Friendly